Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Here are 5 Biopharmaceutical Companies on the Rise
Wall St Cheat Street
Saturday, October 13, 2012 - 11:55am
tags:
Pluristem, Ariad Pharmaceuticals, Sarepta Therapeutics, Amicus Therapeutics, StemCells
Vertex Gets Uneasy On Mixed Clinical Trial Results
Seeking Alpha
Friday, October 12, 2012 - 12:22pm
tags:
Vertex Pharmaceuticals, Kalydeco, cystic fibrosis
ArQule's Tivantinib Failure And Exelixis' Cabozantinib PDUFA: Is There A Correlation?
Seeking Alpha
Friday, October 12, 2012 - 12:17pm
tags:
Arqule, tivantinib, Exelixis, cabozantinib, non-small cell lung cancer
3 Key Issues Spectrum Pharmaceuticals Must Address
Motley Fool
Friday, October 12, 2012 - 12:16pm
tags:
Spectrum Pharmaceuticals, Zevalin
Intercept Pharma, Kythera Bio jump out of the IPO gate
Fierce Biotech
Friday, October 12, 2012 - 12:14pm
tags:
IPOs, Intercept Pharma, Kythera
Watch Amarin Get Crushed By Wall Street
Seeking Alpha
Friday, October 12, 2012 - 12:13pm
tags:
Amarin, Vascepa
Sanofi Aims to Add Second-Generation Lemtrada to Pipeline
Bloomberg
Friday, October 12, 2012 - 12:12pm
tags:
Sanofi, Lemtrada, multiple sclerosis, MS, Genzyme
Diabetes, Carcinoid Syndrome Drive Lexicon's Late-Stage Pipeline
Yahoo/Reuters
Friday, October 12, 2012 - 12:11pm
tags:
diabetes, Lexicon Pharmaceuticals, carcinoid syndrome, LX1032, LX4211
Impax Labs says FDA extends review of Parkinson's disease drug Rytary by 3 months to Jan. 21
Yahoo/AP
Friday, October 12, 2012 - 12:09pm
tags:
Impax Labs, FDA, Rytary, Parkinson's Disease
Celgene Drug Abraxane OK'd For Lung Cancer; Shares Up
Investors.com
Friday, October 12, 2012 - 11:31am
tags:
Celgene, Abraxane, lung cancer, FDA
Abusing pain drug Opana can cause blood disorder-US FDA
Reuters
Friday, October 12, 2012 - 11:30am
tags:
painkiller, Endo, Opana ER, drug abuse
Doctors in Ireland told not to accept trips from drug firms
Irish Times, Ireland
Friday, October 12, 2012 - 11:17am
tags:
physicians, Ireland
Pfizer names top execs for animal-health spinoff
Marketwatch
Friday, October 12, 2012 - 11:15am
tags:
animal health, Pfizer, Zoetis
Novartis drops long-acting version of Vanda Pharmaceuticals drug
Bizjournals.com
Friday, October 12, 2012 - 11:13am
tags:
Novartis, Vanda, Fanapt, schizophrenia
Is a VIVUS Buyout Still on the Table? And if So, by Whom?
Motley Fool
Friday, October 12, 2012 - 11:02am
tags:
Vivus, M&A, Bristol-Myers Squibb, Merck, JNJ, Arena Pharmaceuticals
Genzyme presents second Phase III study of once-daily AUBAGIO
Yahoo/Fly on the Wall
Friday, October 12, 2012 - 11:00am
tags:
Genzyme, Aubagio, MS, multiple sclerosis
A Fresh Look At KERX; High Odds For Zerenex Phase III Success
Yahoo/Reuters
Friday, October 12, 2012 - 10:59am
tags:
Keryx, Zerenex, kidney disease
3 Things to Watch with Abbott's Upcoming Earnings
Motley Fool
Friday, October 12, 2012 - 10:58am
tags:
Abbott Labs, earnings
Pfizer Appeals Court’s Order for CEO to Testify at Trial
Bloomberg
Friday, October 12, 2012 - 10:57am
tags:
Pfizer, Pharma CEOs, Ian Read, Chantix
Here's Why Nektar Therapeutics's Latest Report Might Worry You
Motley Fool
Thursday, October 11, 2012 - 5:48pm
tags:
Nektar

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.